

Applicants : BERMUDES, et al.
U.S. Serial No.: 09/645,415
Filed : August 24, 2000
Page : 3

AMENDMENTS TO THE CLAIMS:

Please cancel claims 1-248 without prejudice to the Applicants' rights to pursue the subject matters in a future application, and add new claims 249-257, as follows:

1.-248. (Canceled)

249. (New) An attenuated tumor-targeted bacteria comprising a first nucleic acid molecule encoding a primary effector molecule operably linked to a promoter and a second nucleic acid molecule encoding a secondary effector molecule, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecule is endostatin, and said secondary effector molecules is bacteriocin release factor (BRP).

250. (New) The attenuated tumor-targeted bacteria of claim 249, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

251. (New) The attenuated tumor-targeted bacteria of claim 249, wherein the Salmonella is an mabB Salmonella mutant.

252. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a first nucleic acid molecule encoding a primary effector molecule operably linked to a promoter and a second nucleic acid molecule encoding a secondary effector molecule, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecule is endostatin, and said secondary effector molecule is bacteriocin release factor (BRP).

Applicants : BERMUDES, et al.
U.S. Serial No.: 09/645,415
Filed : August 24, 2000
Page : 4

253. (New) The pharmaceutical composition of claim 252, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.
254. (New) The pharmaceutical composition of claim 252, wherein the Salmonella is an msbB Salmonella mutant.
255. (New) A method for delivering a primary effector molecule to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a first nucleic acid molecule encoding a primary effector molecule ~~operably linked to a promoter and a second nucleic acid molecule encoding a secondary effector molecule~~, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecules is endostatin, and said secondary effector molecule is bacteriocin release factor (BRP).
256. (New) The method of claim 255, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.
257. (New) The method of claim 255, wherein the Salmonella is an msbB Salmonella mutant.